Big donors distort health services in developing countries

31 August 2008

A report by a USA-based think-tank, the Center for Global Development, has criticized the recent emergence of major aid donors because the scale of their inputs into developing countries, whilst intended to help them cope with HIV/AIDS, has created harmful distortions to local heath care systems.

The three largest aid donors are the Global Fund to Fight AIDS, Tuberculosis and Malaria, the US President's Emergency Plan for AIDS Relief (which was only recently renewed and expanded; Marketletter August 4) and the World Bank's Multi-country AIDS Program (MAP). Since 2000, these three agencies alone have spent $20.0 billion.

Nandini Oomman, the lead author of the study, warned: "the big HIV donors are creating AIDS-specific systems that compete for health workers and administrative effort, share the same inadequate infrastructure and further complicate already complex flows of information."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight